Skip to main content

Antiproliferative Effect of Vitamin D in Prostate Epithelial Cells

  • Chapter
  • 111 Accesses

Abstract

In the last decade, vitamin D and vitamin D analogs have emerged as potential chemotherapeutic agents for the treatment of a variety of cancers. The anticancer activity of vitamin D-based regimens is due, in large part, to inhibition of cell growth and promotion of cellular differentiation. Consistent with these cellular actions, compelling population-based and epidemiologic studies support the protective effects of vitamin D against prostate and certain other cancers. Cell cycle regulation is central to vitamin D’s antiproliferative effects. This chapter focuses primarily on the mechanisms of this cell cycle inhibition in prostate cancer cells and, for illustrative purposes, also highlights vitamin D effects on gene expression and cell cycle in cells derived from other solid tumors. Understanding the fundamental principles of vitamin D synthesis, metabolism and action has led to novel vitamin D-based therapeutic strategies, which are illustrated here. Finally, the possible molecular basis for resistance to vitamin D-mediated growth inhibition is considered.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 2000. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev.; 9:265–270.

    PubMed  CAS  Google Scholar 

  • Baserga R. 2000. Insulin-like growth factor I receptor signalling in prostate cancer cells. Growth Horm IGF Res. 10:S43–44.

    Article  PubMed  Google Scholar 

  • Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. 2001. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28:49–55

    Article  PubMed  CAS  Google Scholar 

  • Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT 1995 Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 5:473–80

    Google Scholar 

  • Bikle DD. 1992. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev. 13:765–784.

    PubMed  CAS  Google Scholar 

  • Blagosklonny MV., Wu GS, Omura S. and El-Deiry WS. 1996. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun., 227, 564–569.

    Article  PubMed  CAS  Google Scholar 

  • Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1997. 1,25-dihydroxyvitamin D3 and 9-cisretinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 138:1491–1497.

    Article  PubMed  CAS  Google Scholar 

  • Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. 2000. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 60:779–782.

    PubMed  CAS  Google Scholar 

  • Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. 1990. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science. 247:712–715.

    Article  PubMed  CAS  Google Scholar 

  • Boyle BJ, Zhao XY, Cohen P, Feldman D. 2001. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol. 165:1319–1324.

    Article  PubMed  CAS  Google Scholar 

  • Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. 1997a. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol. 19:15–27.

    Article  PubMed  CAS  Google Scholar 

  • Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP. 2000. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene. 19:5091–5097.

    Article  PubMed  CAS  Google Scholar 

  • Campbell MJ, Koeffler HP. 1997. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst. 89:182–185.

    Article  PubMed  CAS  Google Scholar 

  • Campbell MJ, Park S, Uskokovic MR, Dawson MI, Koeffler HP. 1998. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analogy. Endocrinology 139:1972–1980.

    Article  PubMed  CAS  Google Scholar 

  • Campbell MJ, Reddy GS, Koeffler HP. 1997b. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 66:413–425.

    Article  PubMed  CAS  Google Scholar 

  • Carlberg C, Polly P. 1998. Gene regulation by vitamin D3. Crit Rev Eukaryot Gene Expr. 8:19–42.

    Article  PubMed  CAS  Google Scholar 

  • Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. 2000. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res. 6:901–908.

    PubMed  CAS  Google Scholar 

  • Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, Malone JM. 1991. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 51:2848–2853.

    PubMed  CAS  Google Scholar 

  • Crescioli C, Maggie M, Vannelli GB, Luconi M, Salerno R, Barni T, Gulisano M, Forti G, Serio M. 2000. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab. 85:2576–2583.

    Article  PubMed  CAS  Google Scholar 

  • Danielpour D. 1996. Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 166:231–239.

    Article  PubMed  CAS  Google Scholar 

  • Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. 1995. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92:5545–5549

    Article  PubMed  CAS  Google Scholar 

  • Djavan B, Waldert M, Seitz C, Marberger M. 2001. Insulin-like growth factors and prostate cancer. World J Urol. 19:225–233.

    Article  PubMed  CAS  Google Scholar 

  • Dusso A, Brown A, Slatopolsky E. 1994. Extrarenal production of calcitriol. Semin Nephrol 14:144–155.

    PubMed  CAS  Google Scholar 

  • Falkenstein E, Tillmann H-C, Christ M., Fuering M. 2000. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacological Reviews 52:513–555.

    PubMed  CAS  Google Scholar 

  • Gardezi SA, Nguyen C, Malloy PJ, Posner GH, Feldman D, Peleg S. 2001. A rationale for treatment of hereditary vitamin D-resistant rickets with analogs of 1 alpha,25-dihydroxyvitamin D(3). J Biol Chem. 276: 29148–29156.

    Article  PubMed  CAS  Google Scholar 

  • Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. 1997. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 50:999–1006.

    Article  PubMed  CAS  Google Scholar 

  • Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61:4315–4319.

    PubMed  CAS  Google Scholar 

  • Grimberg A, Cohen P. 2000. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 183:1–9.

    Article  PubMed  CAS  Google Scholar 

  • Gross C, Skowronski RJ, Plymate SR, Rhim JS, Peehl DM, Feldman D. 1996. Simian virus 40-, but not human papillomavirus-, transformation of prostatic cells results in loss of growth-inhibition by 1,25-dihydroxyvitamin D3 Int J Oncology 8:41–47.

    CAS  Google Scholar 

  • Gross C, Stamey T, Hancock S, Feldman D. 1998. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 159:2035–2039; discussion 2039–2040.

    Article  PubMed  CAS  Google Scholar 

  • Gudas JM, Nguyen H, Li T, Cowan KH. 1995. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res. 55:4561–4565.

    PubMed  CAS  Google Scholar 

  • Guo Y, Kyprianou N. 1998. Overexpression of transforming growth factor TGF-beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 9:185–193.

    PubMed  CAS  Google Scholar 

  • Guyton KZ, Kensler TW, Posner GH. 2001. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol. 41:421–442.

    Article  PubMed  CAS  Google Scholar 

  • Hansen CM, Binderup L, Hamberg KJ, Carlberg C. 2001. Vitamin D and cancer: effects of l,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci. 6:D820–848.

    Article  PubMed  CAS  Google Scholar 

  • Hedlund TE, Moffatt KA, Miller GJ, 1996a. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology. 137:1554–1561.

    Article  PubMed  CAS  Google Scholar 

  • Hedlund TE, Moffatt KA, Miller GJ. 1996b. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol. 58:277–288.

    Article  PubMed  CAS  Google Scholar 

  • Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. 2001. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043–1051.

    PubMed  CAS  Google Scholar 

  • Hsu JY, Feldman D, McNeal JE, Peehl DM. 2001. Reduced lalpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61:2852–2856.

    PubMed  CAS  Google Scholar 

  • Ikonen T, Matikainen M, Mononen N, Hyytinen ER, Helin HJ, Tommola S, Tammela TL, Pukkala E, Schleutker J, Kallioniemi OP, Koivisto PA. 2001. Association of e-cadherin germ-line alterations with prostate cancer. Clin Cancer Res. 7:3465–3471.

    PubMed  CAS  Google Scholar 

  • Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J. 2001. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 15:1370–1380.

    Article  PubMed  CAS  Google Scholar 

  • Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. 2001. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2:203–16.

    Article  PubMed  CAS  Google Scholar 

  • Kim HJ, Abdelkader N, Katz M, McLane JA. 1992. 1,25-Dihydroxy-vitamin-D3 enhances antiproliferative effect and transcription of TGF-beta1 on human keratinocytes in culture. J Cell Physiol. 151:579–587.

    Article  PubMed  CAS  Google Scholar 

  • Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P. 1998. Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol. 66:121–127.

    Article  PubMed  CAS  Google Scholar 

  • Kokontis JM, Hay N, Liao S. 1998. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol. 12:941–953.

    Article  PubMed  CAS  Google Scholar 

  • Kokontis J, Takakura K, Hay N, Liao S. 1994. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54.1566–1573.

    PubMed  CAS  Google Scholar 

  • Koli K, Keski-Oja J. 1995. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res. 55:1540–1546.

    PubMed  CAS  Google Scholar 

  • Koli K, Keski-Oja J. 1993. Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-beta 1 and-beta 2 in cultured murine keratinocytes. Growth Factors 8:153–163.

    Article  PubMed  CAS  Google Scholar 

  • Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH. 1996. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ. 7:1563–1570.

    PubMed  CAS  Google Scholar 

  • Krill D, DeFlavia P, Dhir R, Luo J, Becich MJ, Lehman E, Getzenberg RH. 2001. Expression patterns of vitamin D receptor in human prostate. J Cell Biochem. 82:566–572

    Article  PubMed  CAS  Google Scholar 

  • Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L. 1999. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev. 8:241–248.

    PubMed  CAS  Google Scholar 

  • Ly LH, Zhao XY, Holloway L, Feldman D. 1999. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 140:2071–2076.

    Article  PubMed  CAS  Google Scholar 

  • Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell. 83:841–850.

    Article  PubMed  CAS  Google Scholar 

  • Martin JL, Pattison SL. 2000 Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology. 141:2401–2409.

    Article  PubMed  CAS  Google Scholar 

  • Massague J, Blain SW, Lo RS. 2000. TGF-beta signaling in growth control, cancer, and heritable disorders. Cell. 103:295–309

    Article  PubMed  CAS  Google Scholar 

  • McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O’Malley BW. 1999. Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol. 69:3–12.

    Article  PubMed  CAS  Google Scholar 

  • Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. 1992. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 52:515–520.

    PubMed  CAS  Google Scholar 

  • Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. 1995. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by lalpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997–1003.

    PubMed  CAS  Google Scholar 

  • Miller WL, Portale AA. 2001. Genetics of vitamin D biosynthesis and its disorders. Best Pract Res Clin Endocrinol Metab. 15:95–109.

    Article  PubMed  CAS  Google Scholar 

  • Moffatt KA, Johannes WU, Hedlund TE, Miller GJ. 2001. Growth inhibitory effects of 1 alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res. 61:7122–7129.

    PubMed  CAS  Google Scholar 

  • Moffatt KA, Johannes WU, Miller GJ. 1999. lAlpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 5:695–703.

    PubMed  CAS  Google Scholar 

  • Narvaez CJ, Welsh J. 1997. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant. Endocrinology. 138:4690–4698.

    Article  PubMed  CAS  Google Scholar 

  • Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, and Trump DL 1995. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1: 195–198.

    Article  PubMed  CAS  Google Scholar 

  • Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A. 2001. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 154:369–387.

    Article  PubMed  CAS  Google Scholar 

  • Peehl DM, Seto E, Feldman D. 2001. Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer. Urology. 58:123–126.

    Article  PubMed  CAS  Google Scholar 

  • Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. 1994. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 54:805–810.

    PubMed  CAS  Google Scholar 

  • Platz EA, Hankinson SE, Hollis BW, Colditz GA, Hunter DJ, Speizer FE, Giovannucci E. 2000. Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev. 9:1059–1065.

    PubMed  CAS  Google Scholar 

  • Pols HA, Birkenhager JC, Foekens JA, van Leeuwen JP. 1990. Vitamin D: a modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol. 37:873–876.

    Article  PubMed  CAS  Google Scholar 

  • Rachez C, Freedman LP. 2000. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene. 246:9–21.

    Article  PubMed  CAS  Google Scholar 

  • Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, Uskokovic MR, Campbell MJ. 2001. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 20:1860–1872.

    Article  PubMed  CAS  Google Scholar 

  • Reichrath J. 2001. Will analogs of 1,25-dihydroxyvitamin D(3) (calcitriol) open a new era in cancer therapy? Onkologie. 24:128–133.

    Article  PubMed  CAS  Google Scholar 

  • Sampson ER, Yeh SY, Chang HC, Tsai MY, Wang X, Ting HJ, Chang C. 2001. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells. J Biol Regul Homeost Agents 15:123–129.

    PubMed  CAS  Google Scholar 

  • Saunders DE, Christensen C, Wappler NL, Cho YL, Lawrence WD, Malone JM, Malviya VK, Deppe G. 1993. Additive inhibition of RL95-2 endometrial carcinoma cell growth by carboplatin and 1,25 dihydroxyvitamin D3. Gynecol Oncol. 51:155–159.

    Article  PubMed  CAS  Google Scholar 

  • Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR. 1995. l,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology. 46:365–369.

    Article  PubMed  CAS  Google Scholar 

  • Schwartz GG, Hulka BS. 1990. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 10:1307–11.

    PubMed  CAS  Google Scholar 

  • Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. 1994. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res. 14:1077–1081.

    PubMed  CAS  Google Scholar 

  • Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. 1998. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 7:391–395.

    PubMed  CAS  Google Scholar 

  • Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 103:843–852.

    Article  PubMed  CAS  Google Scholar 

  • Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE. 2000. Proteasomal turnover of p21Cipl does not require p21Cipl ubiquitination. Mol Cell 5:403–410.

    Article  PubMed  CAS  Google Scholar 

  • Skowronski RJ, Peehl DM, Feldman D. 1993. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 132:1952–1960.

    Article  PubMed  CAS  Google Scholar 

  • Skowronski RJ, Peehl DM, Feldman D. 1995. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 136:20–26.

    Article  PubMed  CAS  Google Scholar 

  • Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. 1999. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 5:1339–1345.

    PubMed  CAS  Google Scholar 

  • Umekita Y, Hiipakka RA, Kokontis JM, Liao S. 1996. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA. 93:11802–11807.

    Article  PubMed  CAS  Google Scholar 

  • van den Bernd GJ, Pols HA, van Leeuwen JP. 2000. Anti-tumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs. Curr Pharm Des. 2000 6:717–732.

    Google Scholar 

  • Vaughn JP, Cirisano FD, Huper G. Berchuck A, Futreal PA, Marks JR, Iglehart JD. 1996. Cell cycle control of BRCA2. Cancer Res. 56:4590–4594.

    PubMed  CAS  Google Scholar 

  • Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R. 1998. Action of l,25(OH)2D3 on the cell cycle genes, cyclin Dl, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol. 142:57–65.

    Article  PubMed  CAS  Google Scholar 

  • Walters MR. 1992. Newly identified actions of the vitamin D endocrine system. Endocr Rev. 13:719–764.

    PubMed  CAS  Google Scholar 

  • Wang QM, Jones JB, Studzinski GP. 1996. Cyclin-dependent kinase inhibitor p27 as a mediator of the Gl-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 56:264–267.

    PubMed  CAS  Google Scholar 

  • Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. 1989. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol. 62:79–87.

    Article  PubMed  CAS  Google Scholar 

  • Wu G, Fan RS, Li W, Ko TC, Brattain MG. 1997. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 15:1555–1563.

    Article  PubMed  CAS  Google Scholar 

  • Wu G, Fan RS, Li W, Srinivas V, Brattain MG. 1998. Regulation of transforming growth factor-beta type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues. J Biol Chem 273:7749–7756.

    Article  PubMed  CAS  Google Scholar 

  • Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein, KL Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol Cell Endocrinol (in press)

    Google Scholar 

  • Yang L, Yang J, Venkateswarlu S, Ko T, Brattain MG. 2001. Autocrine TGF-beta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol. 188:383–93.

    Article  PubMed  CAS  Google Scholar 

  • Zhao XY, Ly LH, Peehl DM, Feldman D. 1997. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology. 138:3290–3298.

    Article  PubMed  CAS  Google Scholar 

  • Zhuang SH, Burnstein KL. 1998. Antiproliferative effect of lalpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent Gl accumulation. Endocrinology. 139:1197–207.

    Article  PubMed  CAS  Google Scholar 

  • Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. 1997. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol. 126:83–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Sceince+Business Media New York

About this chapter

Cite this chapter

Burnstein, K.L. (2002). Antiproliferative Effect of Vitamin D in Prostate Epithelial Cells. In: Burnstein, K.L. (eds) Steroid Hormones and Cell Cycle Regulation. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0965-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0965-3_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5327-0

  • Online ISBN: 978-1-4615-0965-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics